logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.

    Article - En anglais

    Objective

    - To evaluate the economic consequences of introducing inactivated poliovirus vaccine (IPV) into the routine vaccination schedule in the United States to reduce vaccine-associated paralytic poliomyelitis (VAPP).

    Design

    - Cost-benefit and cost-effectiveness models were formulated to compare the current national 4-dose live attenuated oral poliovirus vaccine (OPV) schedule with a 4-dose IPV schedule or a sequential schedule of 2 doses of IPV followed by 2 doses of OPV.

    Model assumptions were derived from the National Health Interview Survey (1994), current prices for OPV and IPV, a Delphi panel, compensatory awards by the National Vaccine Injury Compensation Program, and published and unpublished reports.

    Main Outcome Measures

    - Annual societal incremental cost relative to the current schedule for the cost-benefit model ; cost per VAPP case prevented for the cost-effectiveness model.

    Results

    - Changing to an IPV-only or a sequential schedule would cost $28.1 million and $14.7 million, respectively.

    The costs per case of VAPP prevented were estimated as $3.0 million and $3.1 million for each option, respectively.

    Outcomes were most sensitive to the number of additional visits that may occur to avoid multiple injections.

    Conclusions

    - The introduction of IPV into the routine vaccination schedule would not be cost-beneficial at current vaccine prices and with the current compensation awards paid to VAPP cases. (...)

    Mots-clés Pascal : Vaccination, Poliovirus, Enterovirus, Picornaviridae, Virus, Enfant, Homme, Coût, Efficacité, Poliomyélite antérieure, Virose, Infection, Etats Unis, Amérique du Nord, Amérique, Système nerveux pathologie, Système nerveux central pathologie, Moelle épinière pathologie

    Mots-clés Pascal anglais : Vaccination, Poliovirus, Enterovirus, Picornaviridae, Virus, Child, Human, Costs, Efficiency, Acute anterior poliomyelitis, Viral disease, Infection, United States, North America, America, Nervous system diseases, Central nervous system disease, Spinal cord disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0451958

    Code Inist : 002B30A01C. Création : 10/04/1997.